Literature DB >> 33467084

A High-Dimensional Window into the Micro-Environment of Triple Negative Breast Cancer.

Iris Nederlof1, Hugo M Horlings2, Christina Curtis3, Marleen Kok4.   

Abstract

Providing effective personalized immunotherapy for triple negative breast cancer (TNBC) patients requires a detailed understanding of the composition of the tumor microenvironment. Both the tumor cell and non-tumor components of TNBC can exhibit tremendous heterogeneity in individual patients and change over time. Delineating cellular phenotypes and spatial topographies associated with distinct immunological states and the impact of chemotherapy will be necessary to optimally time immunotherapy. The clinical successes in immunotherapy have intensified research on the tumor microenvironment, aided by a plethora of high-dimensional technologies to define cellular phenotypes. These high-dimensional technologies include, but are not limited to, single cell RNA sequencing, spatial transcriptomics, T cell repertoire analyses, advanced flow cytometry, imaging mass cytometry, and their integration. In this review, we discuss the cellular phenotypes and spatial patterns of the lymphoid-, myeloid-, and stromal cells in the TNBC microenvironment and the potential value of mapping these features onto tumor cell genotypes.

Entities:  

Keywords:  breast cancer; immune profiling; single cell; spatial profiling; tumor evolution

Year:  2021        PMID: 33467084      PMCID: PMC7830085          DOI: 10.3390/cancers13020316

Source DB:  PubMed          Journal:  Cancers (Basel)        ISSN: 2072-6694            Impact factor:   6.639


  114 in total

1.  KLRG1+ Effector CD8+ T Cells Lose KLRG1, Differentiate into All Memory T Cell Lineages, and Convey Enhanced Protective Immunity.

Authors:  Dietmar Herndler-Brandstetter; Harumichi Ishigame; Ryo Shinnakasu; Valerie Plajer; Carmen Stecher; Jun Zhao; Melanie Lietzenmayer; Lina Kroehling; Akiko Takumi; Kohei Kometani; Takeshi Inoue; Yuval Kluger; Susan M Kaech; Tomohiro Kurosaki; Takaharu Okada; Richard A Flavell
Journal:  Immunity       Date:  2018-04-03       Impact factor: 31.745

Review 2.  B cells, plasma cells and antibody repertoires in the tumour microenvironment.

Authors:  George V Sharonov; Ekaterina O Serebrovskaya; Diana V Yuzhakova; Olga V Britanova; Dmitriy M Chudakov
Journal:  Nat Rev Immunol       Date:  2020-01-27       Impact factor: 53.106

3.  The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014.

Authors:  R Salgado; C Denkert; S Demaria; N Sirtaine; F Klauschen; G Pruneri; S Wienert; G Van den Eynden; F L Baehner; F Penault-Llorca; E A Perez; E A Thompson; W F Symmans; A L Richardson; J Brock; C Criscitiello; H Bailey; M Ignatiadis; G Floris; J Sparano; Z Kos; T Nielsen; D L Rimm; K H Allison; J S Reis-Filho; S Loibl; C Sotiriou; G Viale; S Badve; S Adams; K Willard-Gallo; S Loi
Journal:  Ann Oncol       Date:  2014-09-11       Impact factor: 32.976

4.  Genomic characterization of metastatic breast cancers.

Authors:  François Bertucci; Charlotte K Y Ng; Anne Patsouris; Thomas Filleron; Christophe Le Tourneau; Fabrice André; Nathalie Droin; Salvatore Piscuoglio; Nadine Carbuccia; Jean Charles Soria; Alicia Tran Dien; Yahia Adnani; Maud Kamal; Séverine Garnier; Guillaume Meurice; Marta Jimenez; Semih Dogan; Benjamin Verret; Max Chaffanet; Thomas Bachelot; Mario Campone; Claudia Lefeuvre; Herve Bonnefoi; Florence Dalenc; Alexandra Jacquet; Maria R De Filippo; Naveen Babbar; Daniel Birnbaum
Journal:  Nature       Date:  2019-05-22       Impact factor: 49.962

5.  IL-6 trans-signaling licenses mouse and human tumor microvascular gateways for trafficking of cytotoxic T cells.

Authors:  Daniel T Fisher; Qing Chen; Joseph J Skitzki; Jason B Muhitch; Lei Zhou; Michelle M Appenheimer; Trupti D Vardam; Emily L Weis; Jessica Passanese; Wan-Chao Wang; Sandra O Gollnick; Mark W Dewhirst; Stefan Rose-John; Elizabeth A Repasky; Heinz Baumann; Sharon S Evans
Journal:  J Clin Invest       Date:  2011-09-19       Impact factor: 14.808

6.  Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy.

Authors:  Carsten Denkert; Gunter von Minckwitz; Silvia Darb-Esfahani; Bianca Lederer; Barbara I Heppner; Karsten E Weber; Jan Budczies; Jens Huober; Frederick Klauschen; Jenny Furlanetto; Wolfgang D Schmitt; Jens-Uwe Blohmer; Thomas Karn; Berit M Pfitzner; Sherko Kümmel; Knut Engels; Andreas Schneeweiss; Arndt Hartmann; Aurelia Noske; Peter A Fasching; Christian Jackisch; Marion van Mackelenbergh; Peter Sinn; Christian Schem; Claus Hanusch; Michael Untch; Sibylle Loibl
Journal:  Lancet Oncol       Date:  2017-12-07       Impact factor: 41.316

7.  The single-cell pathology landscape of breast cancer.

Authors:  Hartland W Jackson; Jana R Fischer; Vito R T Zanotelli; H Raza Ali; Robert Mechera; Savas D Soysal; Holger Moch; Simone Muenst; Zsuzsanna Varga; Walter P Weber; Bernd Bodenmiller
Journal:  Nature       Date:  2020-01-20       Impact factor: 49.962

8.  Pembrolizumab for Early Triple-Negative Breast Cancer.

Authors:  Peter Schmid; Javier Cortes; Lajos Pusztai; Heather McArthur; Sherko Kümmel; Jonas Bergh; Carsten Denkert; Yeon Hee Park; Rina Hui; Nadia Harbeck; Masato Takahashi; Theodoros Foukakis; Peter A Fasching; Fatima Cardoso; Michael Untch; Liyi Jia; Vassiliki Karantza; Jing Zhao; Gursel Aktan; Rebecca Dent; Joyce O'Shaughnessy
Journal:  N Engl J Med       Date:  2020-02-27       Impact factor: 176.079

9.  Human breast tumor-infiltrating CD8+ T cells retain polyfunctionality despite PD-1 expression.

Authors:  Colt A Egelston; Christian Avalos; Travis Y Tu; Diana L Simons; Grecia Jimenez; Jae Y Jung; Laleh Melstrom; Kim Margolin; John H Yim; Laura Kruper; Joanne Mortimer; Peter P Lee
Journal:  Nat Commun       Date:  2018-10-16       Impact factor: 14.919

10.  TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells.

Authors:  Sanjeev Mariathasan; Shannon J Turley; Dorothee Nickles; Alessandra Castiglioni; Kobe Yuen; Yulei Wang; Edward E Kadel; Hartmut Koeppen; Jillian L Astarita; Rafael Cubas; Suchit Jhunjhunwala; Romain Banchereau; Yagai Yang; Yinghui Guan; Cecile Chalouni; James Ziai; Yasin Şenbabaoğlu; Stephen Santoro; Daniel Sheinson; Jeffrey Hung; Jennifer M Giltnane; Andrew A Pierce; Kathryn Mesh; Steve Lianoglou; Johannes Riegler; Richard A D Carano; Pontus Eriksson; Mattias Höglund; Loan Somarriba; Daniel L Halligan; Michiel S van der Heijden; Yohann Loriot; Jonathan E Rosenberg; Lawrence Fong; Ira Mellman; Daniel S Chen; Marjorie Green; Christina Derleth; Gregg D Fine; Priti S Hegde; Richard Bourgon; Thomas Powles
Journal:  Nature       Date:  2018-02-14       Impact factor: 49.962

View more
  4 in total

Review 1.  Multiplex Immunofluorescence and the Digital Image Analysis Workflow for Evaluation of the Tumor Immune Environment in Translational Research.

Authors:  Frank Rojas; Sharia Hernandez; Rossana Lazcano; Caddie Laberiano-Fernandez; Edwin Roger Parra
Journal:  Front Oncol       Date:  2022-06-27       Impact factor: 5.738

Review 2.  Techniques for Profiling the Cellular Immune Response and Their Implications for Interventional Oncology.

Authors:  Tushar Garg; Clifford R Weiss; Rahul A Sheth
Journal:  Cancers (Basel)       Date:  2022-07-26       Impact factor: 6.575

Review 3.  Multiplexed In Situ Spatial Protein Profiling in the Pursuit of Precision Immuno-Oncology for Patients with Breast Cancer.

Authors:  Davide Massa; Anna Tosi; Antonio Rosato; Valentina Guarneri; Maria Vittoria Dieci
Journal:  Cancers (Basel)       Date:  2022-10-06       Impact factor: 6.575

4.  Mapping Intellectual Structures and Research Hotspots of Triple Negative Breast Cancer: A Bibliometric Analysis.

Authors:  Kai-Jun Hao; Xiao Jia; Wen-Ting Dai; Ze-Min Huo; Hua-Qiang Zhang; Jing-Wei Liu; Xiao-Bing Wang
Journal:  Front Oncol       Date:  2022-01-03       Impact factor: 5.738

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.